Mark Berger Net Worth

Mark Berger biography

Dr. Mark Stanley Berger M.D. serves as Chief Medical Officer of the Company. Dr. Berger worked for Kadmon Corporation where he was Senior Vice President, Clinical Research. In this role he was responsible for all clinical aspects of new drug development including designing and managing clinical trials in oncology indications (non-small cell lung cancer and glioblastoma) and non-oncology indications (chronic graft versus host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax, a pan Bcl-2 inhibitor. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011 for a total consideration of $525 million including $225 million in an upfront cash payment. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program (LEAP) that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent and targeted CD33, similar to Actimab-A. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committee meeting.

What is the salary of Mark Berger?

As the Chief Medical Officer of Actinium Pharmaceuticals Inc, the total compensation of Mark Berger at Actinium Pharmaceuticals Inc is $554,364. There are 2 executives at Actinium Pharmaceuticals Inc getting paid more, with Sandesh Seth having the highest compensation of $1,102,720.

How old is Mark Berger?

Mark Berger is 65, he's been the Chief Medical Officer of Actinium Pharmaceuticals Inc since 2017. There are 1 older and 7 younger executives at Actinium Pharmaceuticals Inc. The oldest executive at Actinium Pharmaceuticals Inc is Ajit Shetty, 73, who is the Independent Director.

What's Mark Berger's mailing address?

Mark's mailing address filed with the SEC is 3300 BEE CAVE ROAD, #650-227, AUSTIN, TX, 78746.

Insiders trading at Actinium Pharmaceuticals Inc

Over the last 7 years, insiders at Actinium Pharmaceuticals Inc have traded over $0 worth of Actinium Pharmaceuticals Inc stock and bought 79,730 units worth $38,874 . The most active insiders traders include Anil Kapur, Ajit Shetty y Sandesh Seth. On average, Actinium Pharmaceuticals Inc executives and independent directors trade stock every 41 days with the average trade being worth of $22,211. The most recent stock trade was executed by Sandesh Seth on 10 December 2018, trading 10,000 units of ATNM stock currently worth $4,400.

What does Actinium Pharmaceuticals Inc do?

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

Actinium Pharmaceuticals Inc executives and stock owners

Actinium Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Sandesh Seth,
  Chairman of the Board, Chief Executive Officer
• Sandesh C. Seth M.B.A., M.S., MBA,
  Chairman & CEO
• Mark Berger,
  Chief Medical Officer
• Dale Ludwig,
  Chief Scientific Officer
• Steve O'Loughlin,
  Principal Financial and Accounting Officer
• Steven O'Loughlin BS,
  CFO & Corp. Sec.
• C. David Nicholson,
  Lead Independent Director
• Richard Steinhart,
  Independent Director
• Ajit Shetty,
  Independent Director
• Jeffrey Chell,
  Independent Director
• Dr. Bernie Cunningham P.M.P., Ph.D.,
  Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
• Dr. Arun Swaminathan Ph.D.,
  Chief Bus. & Commercial Officer
• Dr. Avinash Desai M.D.,
  Chief Medical Officer
• Dr. Mamata Gokhale,
  VP & Global Head of Regulatory Affairs
• Dr. Robert N. Daly M.S., Ph.D.,
  VP & Head of Clinical Operations
• Dr. Qing Liang,
  VP & Head of Radiation Sciences
• Dr. Bernie Cunningham,
  Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
• Dr. David Gould,
  Sr. VP of Corp. Devel. & Corp. Affairs
• Dr. Paul Diamond Esq., Ph.D.,
  VP of Patent & Legal Counsel
• Nitya G. Ray,
  Executive VP
• Anil Kapur,
  Chief Commercial Officer